Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (4): 710-715. doi: 10.19723/j.issn.1671-167X.2021.04.015

Previous Articles     Next Articles

Serum LAPTM4B-35 protein as a novel diagnostic marker for hepatocellular carcinoma

PANG Yong,ZHANG Sha,YANG Hua,ZHOU Rou-li()   

  1. Department of Cell Biology, Peking University School of Basic Medical Sciences, Beijing 100191, China
  • Received:2020-05-11 Online:2021-08-18 Published:2021-08-25
  • Contact: Rou-li ZHOU E-mail:rlzhou@bjmu.edu.cn
  • Supported by:
    Beijing Municipal Education Commission ChanXueYan Build Cooperation Projects(ZH100010502)

RICH HTML

   

PDF (PC)

Abstract:

Objective: LAPTM4B-35 protein is one of the isoforms that are encoded by a cancer driver gene, LAPTM4B. This gene was primarily found and identified in our lab of Peking University School of Basic Medical Sciences. The LAPTM4B-35 protein and its encoded mRNA are significantly over-expressed in a variety of cancers, such as hepatocellular carcinoma (HCC), lung cancers (including non small-cell lung cancer and small-cell lung cancer), stomach cancer, colorectal carcinoma, pancreatic cancer, gallbladder cancer, cholangiocarcinoma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, and so on. It has firmly demonstrated through lab experiments either in vivo or in vitro, as well as clinical studies that the over-expression of LAPTM4B-35 can promote cancer growth, metastasis, and multidrug resistance. Specially, the expressive level of LAPTM4B-35 is associa-ted with recurrence of HCC. The aim of this study is to identify the release of LAPTM4B-35 protein from hepatocellular carcinoma into blood of HCC patients and into the medium of cultured HCC cells, and to identify its possible form of LAPTM4B-35 protein existed in blood and cell culture medium, as well as to explore the possibility of LAPTM4B-35 protein as a novel HCC biomarker for diagnosis of HCC and prognosis of HCC patients. Methods: Immunobloting (Western blot) and enzyme-linked immunosorbent assay (ELISA) were used for identification of LAPTM4B-35 protein in the blood of HCC patients and normal individuals. Ultrafiltration and ultracentrifugation were used to isolate and purify exosomes from the culture medium of HCC cells. Results: LAPTM4B-35 protein existed in the blood from HCC patients and normal donors that were demonstrated through Western blot and ELISA. LAPTM4B-35 was also released into the culture medium of HCC cells in the form of exosomes. Preliminary experiments showed that the average and the median of LAPTM4B-35 protein level in the blood of HCC patients (n=43) were both significantly higher than that in the blood of normal donors (n=33) through sandwich ELISA. Conclusion: It is promising that the LAPTM4B-35 protein which is released from HCC cells in the form of exosomes into their extraenvironment may be exploited as a novel cancer biomarker for HCC serological diagnosis.

Key words: Hepatocellular carcinoma, Exosomes, LAPTM4B-35, Biomarkers, tumor

CLC Number: 

  • R735.7

Figure 1

Western blot analysis of LAPTM4B-35 protein in serum of healthy individual and hepatocellular carcinoma patients P1 and P2, serum from HCC patients; H1, serum from normal indivi-dual."

Figure 2

Direct ELISA analysis of LAPTM4B-35 protein in serum of hepatocellular carcinoma patients * P<0.001, serum group vs. blank control group."

Figure 3

SDS-PAGE profiles of cellular extracts and exosomes from BEL-7402 hepatocellular carcinoma cells 1, molecular marker; 2, cellular extracts; 3, exosomes."

Figure 4

Western blot profiles of LAPTM4B-35 protein in membrance extracts from hepatocellular carcinoma tissues and exosomes from BEL-7402 hepatocellular carcinoma cells 1 and 2, tumor tissues; 3 and 4, exosomes."

Figure 5

LAPTM4B-35 protein in exosomes identified by direct ELISA * P<0.001, exosomes group vs. blank control group."

Figure 6

LAPTM4B-35 protein levels in serum from normal individuals and hepatocellular carcinoma patients detected by sandwich ELISA P<0.001, normal vs. HCC. Normal, normal individuals (n=33); HCC, hepatocellular carcinoma patients (n=43)."

[1] Shao GZ, Zhou RL, Zhang QY, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma [J]. Oncogene, 2003, 22(32):5060-5069.
doi: 10.1038/sj.onc.1206832
[2] Yang H, Xiong FX, Lin M, et al. LAPTM4B-35 is a novel diagnostic marker and a prognostic factor of hepatocellular carcinoma [J]. J Surgical Oncology, 2010, 101(5):363-369.
doi: 10.1002/jso.v101:5
[3] Yang H, Xiong FX, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2010, 136(2):275-281.
doi: 10.1007/s00432-009-0659-4 pmid: 19690886
[4] 何静, 邵根泽, 周柔丽, 等. 肝癌中高表达的新基因LAPTM4B对细胞增殖及成瘤性的影响 [J]. 北京大学学报(医学版), 2003, 35(4):348-352.
[5] Li L, Shan Y, Yang H, et al. Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line [J]. Anat Rec (Hoboken), 2011, 294(7):1135-1142.
doi: 10.1002/ar.v294.7
[6] Liu XR, Xiong FX, Wei XH, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of HCC cells [J]. Cancer Sci, 2009, 100(12):2335-2340.
doi: 10.1111/cas.2009.100.issue-12
[7] Li L, Wei XH, Pan YP, et al. LAPTM4B: A novel cancer-asso-ciated gene motivates multi-drug resistance through efflux and activating PI3K/Akt signaling [J]. Oncogene, 2010, 29(43):5785-5795.
doi: 10.1038/onc.2010.303 pmid: 20711237
[8] Yang H, Xiong FX, Wei XH, et al. LAPTM4B-35 promotes growth and metastasis of hepatocelluar carcinoma [J]. Cancer Lett, 2010, 264(2):209-217.
doi: 10.1016/j.canlet.2008.01.025
[9] 刘歆荣, 周柔丽, 张青云, 等. 人肝癌相关新基因编码产物LAPTM4B的鉴定及其生物学特性 [J]. 北京大学学报(医学版), 2003, 35(4):340-347.
[10] Keller S, Sanderson MP, Stoeck A, et al. Exosomes: from biogenesis and secretion to biological function [J]. Immunol Lett, 2006, 107(2):102-108.
doi: 10.1016/j.imlet.2006.09.005
[11] Simons M, Raposo G. Exosomes: vesicular carriers for intercellular communication [J]. Curr Opin Cell Biol, 2009, 21(4):575-581.
doi: 10.1016/j.ceb.2009.03.007
[12] Simpson RJ. Exosomes: proteomic insights and diagnostic potential [J]. Expert Rev Proteomics, 2009, 6(3):267-283.
doi: 10.1586/epr.09.17
[13] Mitchell PJ, Welton J, Staffurth J. Can urinary exosomes act as treatment response markers in prostate cancer? [J]. J Transl Med, 2009, 7:4.
doi: 10.1186/1479-5876-7-4 pmid: 19138409
[14] Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer [J]. Br J Cancer, 2009, 100(10):1603-1607.
doi: 10.1038/sj.bjc.6605058
[15] Théry C, Amigorena S, Raposo G, et al. Isolation and characte-rization of exosomes from cell culture supernatants and biological fluids [J]. Curr Protoc Cell Biol, 2006, Chapter 3: Unit 3.22.
[16] Navabi H, Croston D, Hobot J, et al. Preperation of human ova-rian cancer ascites-derived exosomes for a clinical trial [J]. Blood Cells Mol Dis, 2005, 35(2):149-152.
doi: 10.1016/j.bcmd.2005.06.008
[17] Houali K, Wang X, Shimizu Y, et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1, oncoproteins in the serum and saliva of patients with nasopharyn-geal carcinoma [J]. Clin Cancer Res, 2007, 13(17):4993-5000.
pmid: 17785549
[18] Viaud S, Théry C, Ploix S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what’s next? [J]. Cancer Res, 2010, 70(4):1281-1285.
doi: 10.1158/0008-5472.CAN-09-3276
[19] Koga K, Matsumoto K, Akiyoshi T, et al. Purification, characte-rization and biological significance of tumor-derived exosomes [J]. Anticancer Res, 2005, 25(6A):3703-3707.
[20] Zhou RL. LAPTM4B: a novel diagnostic biomarker and therapeutic target for hepatocellular carcinoma [M]// Wan-Yee Lau. Hepatocellular carcinoma: Basic research. Philippines: InTech Press, 2012: 1-34.
[21] Yang Z, Senninger N, Flammang I, et al. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma [J]. J Cancer Res Clin Oncol, 2019, 145(5):1165-1178.
doi: 10.1007/s00432-019-02863-w
[1] Hai WANG, Yizhou JIANG. Molecular mechanisms and clinical applications of anti-angiogenic therapy in precision treatment of breast cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 251-256.
[2] Bixian LUO, Hongming LIU, Weixun XIE, Weihua GONG. Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 257-265.
[3] Wen DU, Wenbo ZHANG, Yao YU, Shuo LIU, Huiyu SU, Leihao HU, Zunan TANG, Binzhang WU, Zhen CHEN, Jiaqi LI, Hao WANG, Xin PENG. Exploration and clinical application of the "digital and intelligent surgery" diagnosis and treatment workflow for oral and maxillofacial tumors [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 278-284.
[4] Haifeng DONG, Hengxing CHEN, Changhua ZHANG. Research progress on protein lactylation modification in malignant tumors [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 423-430.
[5] Ruofan GAO, Tianyu MA, Runkai WANG, Yuchen YIN, Ruidi LI, Dandan WANG, Bin XIA. Anti-inflammatory effects of cell membrane vesicle-mediated delivery of small interfering RNA targeting tumor necrosis factor-α on dental pulp stem cells [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 22-29.
[6] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[7] Xiangyu SUN, Chao YUAN, Xinzhu ZHOU, Jing DIAO, Shuguo ZHENG. Application of salivary micro-ecosystem in early prevention and control of oral and systemic diseases [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 859-863.
[8] Shaohai TANG, Baoming YANG, Jiankun LI, Lili ZHAO, Yifan WANG, Shunxiang WANG. HDAC2-mediated H3K27 acetylation promotes the proliferation and migration of hepatocellular carcinoma cells [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 884-894.
[9] Congyi YANG, Xiaowen ZHENG, Jingyi CHEN, Jun XU, Feng CHEN, Yang CHEN, Ning CHEN. Protein biomarker screening and functional analysis of salivary exosomes in patients with ulcerative colitis [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 895-902.
[10] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[11] Zhanyi ZHANG, Min LU, Yuehao SUN, Jinghan DONG, Xiaofei HOU, Chunlei XIAO, Guoliang WANG, Xiaojun TIAN, Lulin MA, Hongxian ZHANG, Shudong ZHANG. Clinicopathological features and survival analysis of TFE3-rearranged renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 650-661.
[12] Qi MIAO, Baoan HONG, Xuezhou ZHANG, Zhipeng SUN, Wei WANG, Yuxuan WANG, Yuxuan BO, Jiahui ZHAO, Ning ZHANG. Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 698-703.
[13] Shuai LIU, Zhuo LIU, Yunhe GUAN, Guoliang WANG, Xiaojun TIAN, Hongxian ZHANG, Lei LIU, Lulin MA, Shudong ZHANG. Robot-assisted laparoscopic inferior vena cava segmental resection for renal tumor with tumor thrombus invading the vascular wall [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 796-802.
[14] Chunhui SHENG, Xiao ZHANG, Longwei LV, Yongsheng ZHOU. Exosome derived from human adipose-derived mesenchymal stem cells prevented bone loss induced by estrogen deficiency [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 217-226.
[15] Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG. Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 272-276.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd